<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449681</url>
  </required_header>
  <id_info>
    <org_study_id>TH-CR-602</org_study_id>
    <nct_id>NCT02449681</nct_id>
  </id_info>
  <brief_title>Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS</brief_title>
  <official_title>A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),&#xD;
      a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell&#xD;
      carcinoma of the head and neck or skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, parallel-group, multi-center Phase 2 study in which the pharmacokinetics,&#xD;
      safety, tolerability and efficacy of TH-4000 (Tarloxotinib) will be assessed in participants&#xD;
      with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.&#xD;
&#xD;
      Hypoxia PET scans will be obtained in select centers to analyze potential predictors of tumor&#xD;
      response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with response rate as evaluated by RECIST criteria</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of adverse events (AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events (AEs)</measure>
    <time_frame>Up to 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) calculated for all patients achieving an objective response</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of TH4000 (prodrug) and TH-4000E (TKI effector)</measure>
    <time_frame>Cycle 1 Day 1 predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve of TH4000 (prodrug) and TH-4000E (TKI effector)</measure>
    <time_frame>Cycle 1 Day 1 predose and up to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc Interval</measure>
    <time_frame>Screening, Cycle 1 Day 1, 8, 15 &amp; 22, Day 1 and study Termination</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypoxic volume as measured by Positron Emission Tomography (PET) hypoxia imaging</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin</condition>
  <arm_group>
    <arm_group_label>TH-4000 (Tarloxotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-4000</intervention_name>
    <arm_group_label>TH-4000 (Tarloxotinib)</arm_group_label>
    <other_name>Tarloxotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Confirmed squamous cell carcinoma of the head and neck (oropharynx, oral cavity,&#xD;
             hypopharynx, or larynx) or skin&#xD;
&#xD;
          -  For patients with oropharyngeal cancer, p16 status is known or can be determined&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors version&#xD;
             1.1 (RECIST 1.1)&#xD;
&#xD;
          -  Acceptable laboratory results as indicated by protocol&#xD;
&#xD;
          -  Acceptable cardiac function as indicated by protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior EGFR TKI therapy for recurrent or metastatic SCC (e.g., oral EGFR TKIs&#xD;
             such as erlotinib, gefitinib, or afatinib)&#xD;
&#xD;
          -  Family history of long QTc syndrome&#xD;
&#xD;
          -  Receiving medication that prolongs QT interval ,with a risk of causing Torsades de&#xD;
             Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the&#xD;
             medication&#xD;
&#xD;
          -  Family history of long QTc syndrome&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy&#xD;
&#xD;
          -  Radiation therapy within 2 weeks prior to the first dose of study medication&#xD;
&#xD;
          -  Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose&#xD;
             of study medication&#xD;
&#xD;
          -  Concurrent active malignancy requiring systemic treatment&#xD;
&#xD;
          -  Any other serious uncontrolled medical disorders or psychological conditions that may&#xD;
             interfere with study conduct including but not limited to: clinically significant&#xD;
             active infection&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Hospital Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danny Rischin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California-Norris</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford school of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Cancer Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center (VICC)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>the head and neck</keyword>
  <keyword>skin</keyword>
  <keyword>TH-4000</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Tarloxotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

